Fourth International Prostate Cancer and Urologic Oncology Symposium

Thursday, November 7, 2019, 6:00 AM - Saturday, November 9, 2019, 7:00 PM, Icahn School of Medicine at Mount Sinai (Stern Auditorium), New York, NY


An intense, 3-day educational program combining didactic lectures, point-counterpoint debates, interactive question and answer sessions, in-depth panel discussions, and live surgical demonstrations. The program will focus on providing critical education and training to urologists, oncologists, primary care physicians, and radiologists, as well as medical students, nurse practitioners, registered nurses, physician assistants and researchers. The program will educate and train attendees on issues and procedures related to the identification, treatment, and management of patients with prostate and other urological cancers, which will improve knowledge, competence and performance.

1. Utilize screening techniques for prostate cancer more efficiently to reduce the numbers of biopsies and diagnosis of clinically insignificant prostate cancer.
2. Discuss effective management of treatment failure in prostate cancer to help reduce mortality.
3. Describe the most recent approach to treating locally advanced and metastatic urologic disorders.
4. Identify the technical challenges of robotic urologic oncologic surgery.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (26.25 hours), Non-Physician Attendance (26.25 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.